Short Interest in Lumos Pharma, Inc. (NASDAQ:LUMO) Decreases By 69.7%

Lumos Pharma, Inc. (NASDAQ:LUMO) was the target of a large decline in short interest in October. As of October 31st, there was short interest totalling 86,400 shares, a decline of 69.7% from the October 15th total of 285,400 shares. Based on an average daily trading volume, of 100,300 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.5% of the shares of the stock are sold short.

Lumos Pharma Stock Down 0.2 %

Lumos Pharma stock traded down $0.01 during midday trading on Tuesday, hitting $4.36. 141,303 shares of the stock were exchanged, compared to its average volume of 49,955. Lumos Pharma has a 52 week low of $1.37 and a 52 week high of $4.58. The stock has a market capitalization of $35.42 million, a PE ratio of -1.02 and a beta of 0.76. The company has a fifty day simple moving average of $3.97 and a two-hundred day simple moving average of $2.97.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. EF Hutton Acquisition Co. I upgraded shares of Lumos Pharma to a “strong-buy” rating in a research report on Tuesday, September 24th. HC Wainwright reaffirmed a “neutral” rating and set a $4.25 price target on shares of Lumos Pharma in a report on Friday. Finally, Oppenheimer reduced their price objective on Lumos Pharma from $16.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd.

Institutional Trading of Lumos Pharma

A hedge fund recently raised its stake in Lumos Pharma stock. Private Advisor Group LLC grew its holdings in Lumos Pharma, Inc. (NASDAQ:LUMO) by 2,380.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 744,513 shares of the company’s stock after purchasing an additional 714,500 shares during the period. Private Advisor Group LLC owned about 9.17% of Lumos Pharma worth $2,881,000 at the end of the most recent quarter. 33.99% of the stock is currently owned by hedge funds and other institutional investors.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.